Skip to main navigation Skip to search Skip to main content

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics

  • Matthew J. Roberts*
  • , Nathan Papa
  • , Hans Veerman
  • , Katelijne de Bie
  • , Andrew Morton
  • , Anthony Franklin
  • , Sheliyan Raveenthiran
  • , William J. Yaxley
  • , Maarten L. Donswijk
  • , Henk G. van der Poel
  • , Hemamali Samaratunga
  • , David Wong
  • , Nicholas Brown
  • , Robert Parkinson
  • , Troy Gianduzzo
  • , Boon Kua
  • , Geoffrey D. Coughlin
  • , Daniela E. Oprea-Lager
  • , Louise Emmett
  • , Pim J. van Leeuwen
  • John W. Yaxley, André N. Vis
*Corresponding author for this work
  • Royal Brisbane and Women's Hospital
  • University of Queensland
  • Monash University
  • Antoni van Leeuwenhoek Hospital
  • Amsterdam UMC - University of Amsterdam
  • Prostate Cancer Network Netherlands
  • Aquesta Uropathology
  • UnitingCare Health
  • Amsterdam UMC
  • University of New South Wales
  • St. Vincent's Hospital Sydney

Research output: Contribution to journalArticleAcademicpeer-review

32 Downloads (Pure)

Abstract

Objectives: To construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. Patients and Methods: Patients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence-free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre- and post-surgical parameters and primary tumour maximum standardised uptake value (SUVmax) on diagnostic PSMA-PET/CT. Calibration was assessed in an external dataset from the Netherlands with the same inclusion criteria. Results: Data from 846 patients were used to develop the models. Tumour SUVmax was associated with worse predicted 3-year BRFS for both pre- and post-surgical models. SUVmax change from 4 to 16 lessened the predicted 3-year BRFS from 66% to 42% for a patient aged 65 years with typical pre-surgical parameters (PSA level 8 ng/mL, Prostate Imaging-Reporting and Data System score 4/5 and biopsy Gleason score ≥4 + 5). Considering post-surgical variables, a patient with the same age and PSA level but pathological stage pT3a, RP Gleason score ≥4 + 5 and negative margins, SUVmax change from 4 to 16 lessened the predicted 3-year BRFS from 76% to 61%. Calibration on an external sample (n = 464) showed reasonable performance; however, a tendency to overestimate survival in patients with good prognostic factors was observed. Conclusion: Tumour SUVmax on diagnostic PSMA-PET/CT has utility additional to commonly recognised variables for prediction of BRFS after RP.
Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalBJU international
Volume134
Issue numberS2
Early online date2024
DOIs
Publication statusPublished - Dec 2024

Keywords

  • Gleason score
  • PET/CT
  • PSMA
  • Prostate-specific membrane antigen
  • biochemical failure
  • radical prostatectomy

Fingerprint

Dive into the research topics of 'Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics'. Together they form a unique fingerprint.

Cite this